Business, energy, technology, markets and global industry news from Business News Today

IceCure Medical

PharmaDeviceNews IceCure Medical
IceCure Medical’s ChoICE post-market study is evaluating the ProSense cryoablation system as a minimally invasive treatment option for eligible older patients with low-risk, early-stage breast cancer. Representative image.
Medical Devices & Diagnostics

What will IceCure Medical’s ChoICE study reveal about ProSense breast cancer cryoablation?

IceCure Medical launches the ChoICE post-market study at West Cancer Center, testing ProSense adoption and five-year outcomes in breast cancer.

Read More
A clinician performs an ultrasound-guided breast cryoablation procedure as IceCure Medical expands ProSense installations for minimally invasive treatment of selected low-risk breast cancer patients. Representative image.
Medical Devices & Diagnostics

Can IceCure Medical turn 70% ProSense installation growth into durable breast cancer revenue?

IceCure Medical’s FDA-authorised breast cancer cryoablation platform is gaining United States installations, but narrow eligibility, postmarket evidence requirements and heavy dilution complicate the small-cap investment case.

Read More